Development and Psychometric Validation of a Patient-Reported Outcome Measure for Arm Lymphedema: The LYMPH-Q Upper Extremity Module.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
07
10
2020
accepted:
15
02
2021
pubmed:
6
7
2021
medline:
12
8
2021
entrez:
5
7
2021
Statut:
ppublish
Résumé
A multiphased mixed-methods study was performed to develop and validate a comprehensive patient-reported outcome measure (PROM) for arm lymphedema in women with breast cancer (i.e., the LYMPH-Q Upper Extremity Module). Qualitative interviews (January 2017 and June 2018) were performed with 15 women to elicit concepts specific to arm lymphedema after breast cancer treatment. Data were audio-recorded, transcribed, and coded. Scales were refined through cognitive interviews (October and Decemeber 2018) with 16 patients and input from 12 clinical experts. The scales were field-tested (October 2019 and January 2020) with an international sample of 3222 women in the United States and Denmark. Rasch measurement theory (RMT) analysis was used to examine reliability and validity. The qualitative phase resulted in six independently functioning scales that measure arm symptoms, function, appearance, psychological function, and satisfaction with information and with arm sleeves. In the RMT analysis, all items in each scale had ordered thresholds and nonsignificant chi-square p values. For all the scales, the reliability statistics with and without extremes for the Person Separation Index were 0.80 or higher, Cronbach's alpha was 0.89 or higher, and the Intraclass Correlation Coefficients were 0.92 or higher. Lower (worse) scores on the LYMPH-Q Upper Extremity scales were associated with reporting of more severe arm swelling, an arm problem caused by cancer and/or its treatment, and wearing of an arm sleeve in the past 12 months. The LYMPH-Q Upper Extremity Module can be used to measure outcomes that matter to women with upper extremity lymphedema. This new PROM was designed using a modern psychometric approach and, as such, can be used in research and in clinical care.
Sections du résumé
BACKGROUND
BACKGROUND
A multiphased mixed-methods study was performed to develop and validate a comprehensive patient-reported outcome measure (PROM) for arm lymphedema in women with breast cancer (i.e., the LYMPH-Q Upper Extremity Module).
METHODS
METHODS
Qualitative interviews (January 2017 and June 2018) were performed with 15 women to elicit concepts specific to arm lymphedema after breast cancer treatment. Data were audio-recorded, transcribed, and coded. Scales were refined through cognitive interviews (October and Decemeber 2018) with 16 patients and input from 12 clinical experts. The scales were field-tested (October 2019 and January 2020) with an international sample of 3222 women in the United States and Denmark. Rasch measurement theory (RMT) analysis was used to examine reliability and validity.
RESULTS
RESULTS
The qualitative phase resulted in six independently functioning scales that measure arm symptoms, function, appearance, psychological function, and satisfaction with information and with arm sleeves. In the RMT analysis, all items in each scale had ordered thresholds and nonsignificant chi-square p values. For all the scales, the reliability statistics with and without extremes for the Person Separation Index were 0.80 or higher, Cronbach's alpha was 0.89 or higher, and the Intraclass Correlation Coefficients were 0.92 or higher. Lower (worse) scores on the LYMPH-Q Upper Extremity scales were associated with reporting of more severe arm swelling, an arm problem caused by cancer and/or its treatment, and wearing of an arm sleeve in the past 12 months.
CONCLUSIONS
CONCLUSIONS
The LYMPH-Q Upper Extremity Module can be used to measure outcomes that matter to women with upper extremity lymphedema. This new PROM was designed using a modern psychometric approach and, as such, can be used in research and in clinical care.
Identifiants
pubmed: 34224044
doi: 10.1245/s10434-021-09887-y
pii: 10.1245/s10434-021-09887-y
pmc: PMC8349351
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5166-5182Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : Canadian Cancer Society Research Institute
ID : 706256
Organisme : Canadian Breast Cancer Foundation
ID : 319371
Organisme : NCI NIH HHS
ID : P30CA008748
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
Qual Life Res. 2010 Oct;19(8):1087-96
pubmed: 20512662
J Cancer Surviv. 2013 Mar;7(1):83-92
pubmed: 23212603
Value Health. 2005 Mar-Apr;8(2):94-104
pubmed: 15804318
Value Health. 2011 Dec;14(8):967-77
pubmed: 22152165
Med Care. 1989 Mar;27(3 Suppl):S217-32
pubmed: 2646490
Ann Surg Oncol. 2021 Mar;28(3):1656-1668
pubmed: 33249519
Lymphology. 2010 Mar;43(1):1-13
pubmed: 20552814
Value Health. 2011 Dec;14(8):978-88
pubmed: 22152166
Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):62-70
pubmed: 30165125
Cancers (Basel). 2020 Jan 06;12(1):
pubmed: 31935796
Health Technol Assess. 2009 Feb;13(12):iii, ix-x, 1-177
pubmed: 19216837
Qual Life Res. 2002 May;11(3):193-205
pubmed: 12074258
Restor Dent Endod. 2013 Feb;38(1):52-4
pubmed: 23495371
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Lancet Oncol. 2013 May;14(6):500-15
pubmed: 23540561
J Clin Epidemiol. 2003 Jan;56(1):52-60
pubmed: 12589870
Crit Rev Oncol Hematol. 2014 Dec;92(3):227-34
pubmed: 25085806
Qual Life Res. 2003 May;12(3):229-38
pubmed: 12769135
Appl Psychol Meas. 2017 May;41(3):178-194
pubmed: 29881087
Breast Cancer Res Treat. 2017 Jun;163(2):281-286
pubmed: 28265793
J Clin Epidemiol. 2007 Jan;60(1):34-42
pubmed: 17161752
Breast. 2017 Dec;36:67-73
pubmed: 28992556
Health Qual Life Outcomes. 2006 Oct 11;4:79
pubmed: 17034633
Qual Life Res. 2018 May;27(5):1159-1170
pubmed: 29550964
Qual Life Res. 2018 May;27(5):1147-1157
pubmed: 29435801
Plast Reconstr Surg. 2009 Aug;124(2):345-353
pubmed: 19644246
Cancers (Basel). 2020 Feb 29;12(3):
pubmed: 32121343